ALPHA TAU MEDICAL LTD
DRTSNASDAQTrading Snapshot
- Day Range
- $15.04 – $15.36
- 52-Week Range
- $3.43 – $15.79
- Volume
- $3.37B
- Avg Volume
- $4.43B
- Shares Outstanding
- 90.3M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $174M
- Last Q Revenue
- $46M
- P/E Ratio
- -14.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +22.2%
Why Investors Own DRTS
- ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALPHA TAU MEDICAL LTD
DRTS
StockOtter · stockotter.spaceAbout ALPHA TAU MEDICAL LTD
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete respon
Alpha Tau to Participate in September Investor Conferences
JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast
PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its in